Compare Ascendis Pharma A/S (ASND) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Shell PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Shell PLC trades at $82.4 (market cap $222.30B). The key difference: Shell PLC is far larger — about 12.5× Ascendis Pharma A/S's market cap, and Shell PLC pays a 3.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SHEL | |
|---|---|---|
Market Cap | $17.74B | $222.30B |
Sector | Health | Energy |
52-Week High | $277.18 | $94.15 |
52-Week Low | $163.32 | $70.28 |
Enterprise Value | $18.11B | $274.83B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SHEL trades at $82.23, up 1.02% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.81 and net income margin of 7.01%. Recent Q1 2026 earnings beat expectations, and the company raised its Q2 outlook despite Middle East production disruptions. Analyst consensus is strongly bullish with a $122.20 price target.
The outlook for SHEL is positive, supported by elevated energy prices and strong gas trading, though geopolitical risks and declining operating cash flow pose headwinds. The stock offers value with attractive valuation multiples and a solid dividend, but investors should monitor production volatility and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
